# OnCo record paper-nct05227664-nat-med-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct05227664-nat-med-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct05227664-nat-med-2026" ;
  schema:name "First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial"@en ;
  schema:description "Published report from the trial registered as NCT05227664, in Nature Medicine (2026), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct05227664-nat-med-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-026-04564-7>, <https://pubmed.ncbi.nlm.nih.gov/42587052/>, <https://europepmc.org/article/MED/42587052>, <https://clinicaltrials.gov/study/NCT05227664> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1038/s41591-026-04564-7> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Shao X, Tian C, Chen Z, et al." ;
  onco:trials <https://onco.cc/trials/nct05227664/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .